JPH0578252A - Placenta or liver extract with stable sod activity and external agent composition containing the same - Google Patents
Placenta or liver extract with stable sod activity and external agent composition containing the sameInfo
- Publication number
- JPH0578252A JPH0578252A JP3097720A JP9772091A JPH0578252A JP H0578252 A JPH0578252 A JP H0578252A JP 3097720 A JP3097720 A JP 3097720A JP 9772091 A JP9772091 A JP 9772091A JP H0578252 A JPH0578252 A JP H0578252A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- placenta
- sod activity
- liver
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、胎盤または肝臓の抽出
液をプロテアーゼで酵素分解し、分子量１０，０００以
下の物質を除去して得られる安定なＳＯＤ活性を有する
抽出液（以下単に抽出液という場合がある）およびそれ
を含有することを特徴とする安全な外用剤組成物に関す
るものである。TECHNICAL FIELD The present invention relates to an extract having a stable SOD activity obtained by enzymatically decomposing a placenta or liver extract with a protease to remove substances having a molecular weight of 10,000 or less (hereinafter simply referred to as an extract. In some cases) and a safe external preparation composition containing the same.
【０００２】[0002]
【従来の技術】ラジカルスカベンジャーであるＳＯＤ
（スーパーオキシドジィスムターゼ）は、人間を含めて
広く動物および微生物に存在する一種の生体防御酵素で
あり、細胞内において有害で反応性の高い活性酵素、例
えばスーパーオキシドラジカル（Ｏ2 ) , ヒドロキシル
ラジカル( ・ＯＨ）等の活性酸素種の濃度を低下させる
ことから、生命の恒常性維持に係わる重要な酵素として
注目されている。2. Description of the Related Art SOD which is a radical scavenger
(Superoxide dismutase) is a kind of bioprotective enzyme that is widely present in animals and microorganisms including humans, and is an active enzyme that is harmful and highly reactive in cells, such as superoxide radical (O 2 ), hydroxyl. Since it reduces the concentration of reactive oxygen species such as radicals (.OH), it is attracting attention as an important enzyme involved in maintaining homeostasis of life.
【０００３】例えば、胎盤エキスにＳＯＤが含まれてい
ることは公知であり（特開昭６１−２７７６２６号公
報）、ヒト胎盤からＳＯＤを単離する製造法も知られて
いる（特開昭５６−１０２７８７号公報、特開昭５７−
１５５９９１号公報）。For example, it is known that placenta extract contains SOD (JP-A-61-277626), and a production method for isolating SOD from human placenta is also known (JP-A-56). -102787, JP-A-57-
155991).
【０００４】また、ＳＯＤには強い抗炎症作用や皮膚の
紅斑抑制作用があることが、ラット・カラゲニン足浮腫
試験などによって認められており〔Ｏｙａｎａｇｕｉ．
Ｙ．：Ｉｎｈｉｂｉｔｉｏｎ ｏｆ ｓｕｐｅｒｏｘｉ
ｄｅ ａｎｉｏｎｓ ａｔｔｈｅ ｐｒｏｓｔａｇｌａ
ｎｄｉｎ ｐｈａｓｅ ｏｆ ｃａｒｒａｇｅｅｎａｎ
ｆｏｏｔ−ｏｅｄｅｍａ．Ｂｉｏｃｈｅｍ．Ｐｈａｒ
ｍａｃｏｌ．２５：１４６５−１４７２，１９７６：Ａ
ｋｉｒａ Ｙ．，Ｙｏｓｈｉｋｉ Ｍ．，Ｍｉｙａｃｈ
ｉ Ｉ．，Ｊ．Ｄｅｒｍｔｏｌ．，１４，５６９（１９
８７）〕、関連の技術も開示されている（例えば、特開
昭５６−７７２０号公報など）。Further, it has been confirmed by the rat carrageenin paw edema test that SOD has a strong anti-inflammatory effect and an erythema suppressing effect on the skin [Oyanagui.
Y. : Inhibition of superoxi
de anions at the prostagla
ndin phase of carrageenan
foot-oedema. Biochem. Phar
macol. 25: 1465-1472, 1976: A
Kira Y. , Yoshi M. , Miyach
i I. , J. Dermtol. , 14,569 (19
87)], and related technologies are also disclosed (for example, Japanese Patent Laid-Open No. 56-7720).
【０００５】さらに、ＳＯＤの種々の特性を利用した化
粧料も知られている（例えば、特公昭５９−１０３２４
号公報、特開昭５５−８７７１２号公報など）。Furthermore, cosmetics utilizing various characteristics of SOD are also known (for example, Japanese Patent Publication No. 59-10324).
JP-A-55-87712, etc.).
【０００６】[0006]
【発明が解決しようとする課題】しかしながら、ＳＯＤ
は優れた特性があるにもかかわらず、本来不安定な酵素
であるため、特に水溶液の状態で保存した時にＳＯＤ活
性を失ったり、濁りが生じる等の問題があった。[Problems to be Solved by the Invention] However, SOD
Despite having excellent properties, since it is an enzyme that is inherently unstable, there were problems such as loss of SOD activity and turbidity especially when stored in an aqueous solution.
【０００７】したがって、従来技術によって得られた原
料を、例えば化粧料の有効成分として配合しても、ＳＯ
Ｄそのものの効果が発揮されなかったり、色や臭いが経
時的に変化することなどによって商品価値を損なう問題
があるため、安定なＳＯＤ活性を有する原料や製剤の開
発が望まれていた。Therefore, even if the raw material obtained by the conventional technique is blended as an active ingredient of cosmetics, for example, SO
Development of raw materials and preparations having stable SOD activity has been desired because there is a problem that the commercial value is impaired because the effect of D itself is not exerted or the color and odor change with time.
【０００８】本発明は、このような現状に鑑みてなされ
たもので、安定なＳＯＤ活性を有する胎盤または肝臓抽
出液およびそれを配合することを特徴とする外用剤組成
物を提供することを目的とするものである。The present invention has been made in view of the above circumstances, and an object thereof is to provide a placenta or liver extract having stable SOD activity and an external preparation composition containing the extract. It is what
【０００９】[0009]
【課題を解決するための手段】本発明者らは鋭意研究の
結果、胎盤または肝臓の抽出液をプロテアーゼで酵素分
解し、酵素分解して得られる分子量１０，０００以下の
物質を除去することによって、安定なＳＯＤの活性を有
する抽出液が得られ、これを外用剤基剤に配合すること
で、ＳＯＤの活性低下が著しく改善された外用剤組成物
が得られることを見出し本発明を完成した。Means for Solving the Problems As a result of earnest studies, the present inventors have found that the extract of placenta or liver is enzymatically decomposed by a protease and the substance having a molecular weight of 10,000 or less obtained by the enzymatic decomposition is removed. It was found that an extract having a stable SOD activity can be obtained, and by adding this to an external preparation base, an external preparation composition in which SOD activity decrease is remarkably improved can be obtained, and the present invention has been completed. ..
【００１０】本発明の外用剤組成物に配合する抽出液
は、胎盤または肝臓に水、水とアルコールなどの有機溶
媒との混合溶媒を使用して一般の抽出法により抽出した
液に、ＳＯＤ活性が失活しない一定のｐＨ、温度条件下
でプロテアーゼを作用させ、蛋白質を酵素分解した後、
分子量１０，０００以下のものを除去することによって
得られる。The extract to be added to the external preparation composition of the present invention has a SOD activity which is obtained by a general extraction method using water or a mixed solvent of water and an organic solvent such as alcohol for the placenta or liver. After the protease is made to act under the constant pH and temperature conditions that do not inactivate the protein,
It is obtained by removing those having a molecular weight of 10,000 or less.
【００１１】本発明で使用する胎盤または肝臓の種類は
特に制限されないが、胎盤の場合は、ヒト，ウシ，ウ
マ，ブタなどが好適であり、肝臓の場合はウシ，ウマ，
ブタ，トリなどが好適に使用される。The type of placenta or liver used in the present invention is not particularly limited. In the case of placenta, humans, cattle, horses, pigs and the like are preferable, and in the case of liver, cattle, horses,
Pigs and birds are preferably used.
【００１２】蛋白分解酵素を作用させる場合は、ＳＯＤ
の活性を維持させる必要があることから、ｐＨは５〜
９、好ましくは６．５〜８．５、温度は５〜５０℃、好
ましくは２０〜４０℃の反応条件が良い。蛋白質を分解
する際に用いる酵素は、中性プロテアーゼ（例 アクチ
ナーゼＥ（科研製薬製））、パパイン、トリプシンが好
適に使用される。When a protease is used, SOD is used.
Since it is necessary to maintain the activity of
9, preferably 6.5 to 8.5, the temperature is 5 to 50 ° C, and preferably 20 to 40 ° C. As an enzyme used for decomposing a protein, neutral protease (eg, actinase E (produced by Kaken Pharmaceutical Co., Ltd.)), papain, and trypsin are preferably used.
【００１３】さらに、蛋白分解酵素液中からＳＯＤを不
安定にする要因を取り除くために、限外濾過や透析膜を
利用して濾過するなど通常の操作で分子量１０，０００
以下の物質を除去する。Further, in order to remove the factor that makes SOD unstable from the proteolytic enzyme solution, the molecular weight is 10,000 by a usual operation such as ultrafiltration or filtration using a dialysis membrane.
Remove the following substances.
【００１４】このようにして得られる本発明の抽出液
は、安定なＳＯＤ活性を有ししかも皮膚に対する刺激が
殆どないため、これを外用剤基剤に配合することによっ
て、臭いや色調の経時変化の少ない安定なＳＯＤ活性を
有する安全な外用剤組成物を提供することができる。The thus-obtained extract of the present invention has a stable SOD activity and almost no irritation to the skin. Therefore, by adding it to an external preparation base, changes in odor and color tone with time. It is possible to provide a safe external preparation composition having a stable SOD activity with a small amount.
【００１５】本発明の抽出液を配合した製剤の剤型は、
外用の形態であれば特に制限はなく、医薬品や化粧料に
通常に用いられる剤型、例えば化粧水、クリーム、乳
液、パック、エッセンス、軟膏剤、乳剤など種々の基剤
を使用することができる。但し、クリームなどの製造工
程中、乳化時の長時間の高温加熱はＳＯＤの活性が損な
われることから好ましくなく、必ず４５℃以下の条件で
抽出液を添加、攪拌することが望まれる。The dosage form of the preparation containing the extract of the present invention is
There is no particular limitation so long as it is a form for external use, and various bases such as a dosage form usually used for medicines and cosmetics, for example, lotion, cream, emulsion, pack, essence, ointment, emulsion can be used. .. However, during the manufacturing process of cream or the like, heating at high temperature for a long time during emulsification is not preferable because the activity of SOD is impaired, and it is always desirable to add and stir the extract under conditions of 45 ° C or lower.
【００１６】本発明の抽出液を前記基剤に配合する場
合、外用剤の全量に対して０．０１〜５０．０％（重
量）で、好適には０．１〜３０％（重量）が使用され
る。When the extract of the present invention is added to the above-mentioned base, it is 0.01 to 50.0% (weight), preferably 0.1 to 30% (weight) with respect to the total amount of the external preparation. used.
【００１７】以下、実施例によって本発明を詳細に説明
する。The present invention will be described in detail below with reference to examples.
【００１８】[0018]
製造例 １ ウシ胎盤１ｋｇを冷生理食塩水で洗浄した後細切し、精
製水２ｋｇを加え、３０℃で３時間攪拌しながら抽出す
る。次に、これを遠心分離（８，０００ｒｐｍ、２０分
間、５℃）後、上清液をとり弱塩基性（ｐＨ７．３）に
調整し、アクチナーゼＥ（科研製薬製）を加え、３０℃
で５時間攪拌する。さらにこの溶液を酸性（ｐＨ４．
５）にし、遠心分離（８，０００ｒｐｍ、１０分間、５
℃）後中性（ｐＨ７．０）にし、透析膜処理で分子量１
０，０００以下の物質を取り除いてＳＯＤ活性１０，５
００ｕｎｉｔ／ｍｌを有するウシ胎盤抽出液を得た。Production Example 1 1 kg of bovine placenta is washed with cold physiological saline and then finely chopped, 2 kg of purified water is added, and the mixture is extracted with stirring at 30 ° C. for 3 hours. Next, after centrifuging this (8,000 rpm, 20 minutes, 5 ° C.), the supernatant is taken and adjusted to be weakly basic (pH 7.3), and actinase E (produced by Kaken Pharmaceutical Co., Ltd.) is added thereto, and the temperature is 30 ° C.
Stir for 5 hours. Furthermore, this solution was acidified (pH 4.
5) and centrifuge (8,000 rpm, 10 minutes, 5
℃) after neutralization (pH 7.0), the molecular weight of 1 by dialysis membrane treatment
SOD activity of 10,5
A bovine placenta extract having 00 unit / ml was obtained.
【００１９】製造例 ２ ウマ肝臓１ｋｇを冷生理食塩水で洗浄した後細切し、精
製水３ｋｇを加え、４０℃で３時間攪拌しながら抽出す
る。次に、これを遠心分離（８，０００ｒｐｍ、２０分
間、５℃）後、上清液をとり弱塩基性（ｐＨ８．０）に
調整し、アクチナーゼＥ（科研製薬製）を加え、２０℃
で６時間攪拌する。さらにこの溶液を酸性（ｐＨ４．
５）にし、遠心分離（８，０００ｒｐｍ、１０分間、５
℃）後中性（ｐＨ７．０）にし、限外濾過で分子量１
０，０００以下の物質を取り除いてＳＯＤ活性２５，０
００ｕｎｉｔ／ｍｌを有するウマ肝臓抽出液を得た。Production Example 2 1 kg of horse liver was washed with cold physiological saline and then finely chopped, 3 kg of purified water was added, and the mixture was extracted at 40 ° C. for 3 hours with stirring. Next, after centrifuging this (8,000 rpm, 20 minutes, 5 ° C.), the supernatant was taken and adjusted to be weakly basic (pH 8.0), and actinase E (produced by Kaken Pharmaceutical Co., Ltd.) was added, and the temperature was adjusted to 20 ° C.
Stir for 6 hours. Furthermore, this solution was acidified (pH 4.
5) and centrifuge (8,000 rpm, 10 minutes, 5
℃) after neutralization (pH 7.0), ultrafiltration has a molecular weight of 1
SOD activity of 25,0 by removing less than 10,000 substances
An equine liver extract with 00 unit / ml was obtained.
【００２０】製造例 ３ ブタ胎盤１ｋｇを冷生理食塩水で洗浄した後細切し、精
製水とエタノール混液１：１）２ｋｇを加え、３０℃で
３時間攪拌しながら抽出する。次に、これを遠心分離
（８，０００ｒｐｍ、２０分間、５℃）後、上清液を取
りパパインを加え、２５℃で５時間攪拌する。さらにこ
の溶液を酸性（ｐＨ４．５）にし、遠心分離（８，００
０ｒｐｍ、１０分間、５℃）後中性（ｐＨ７．０）に
し、限外濾過で分子量１０，０００以下の物質を取り除
き、ＳＯＤ活性３，０００ｕｎｉｔ／ｍｌを有するブタ
胎盤抽出液を得た。Production Example 3 1 kg of pig placenta is washed with cold physiological saline and then finely chopped, 2 kg of a mixture of purified water and ethanol 1: 1) is added, and the mixture is extracted at 30 ° C. for 3 hours with stirring. Next, this is centrifuged (8,000 rpm, 20 minutes, 5 ° C.), the supernatant is removed, papain is added, and the mixture is stirred at 25 ° C. for 5 hours. The solution was acidified (pH 4.5) and centrifuged (8,000
The mixture was neutralized (pH 7.0) after 0 rpm for 10 minutes at 5 ° C., and substances having a molecular weight of 10,000 or less were removed by ultrafiltration to obtain a pig placenta extract having SOD activity of 3,000 units / ml.
【００２１】製造例 ４ ウシ肝臓１ｋｇを冷生理食塩水で洗浄した後細切し、精
製水３ｋｇを加え、３５℃で３時間攪拌しながら抽出す
る。次に、これを遠心分離（８，０００ｒｐｍ、２０分
間、５℃）後、上清液を取り、トリプシンを加え、１５
℃で８時間攪拌する。さらにこの溶液を酸性（ｐＨ５．
０）にし、遠心分離後（８，０００ｒｐｍ、１０分間、
５℃）中性（ｐＨ７．０）にし、透析膜を用いて分子量
１０，０００以下の物質を取り除いてＳＯＤ活性２３，
０００ｕｎｉｔ／ｍｌを有するウシ肝臓抽出液を得た。Production Example 4 1 kg of bovine liver was washed with cold physiological saline and then minced, 3 kg of purified water was added, and the mixture was extracted at 35 ° C. for 3 hours with stirring. Next, after centrifuging this (8,000 rpm, 20 minutes, 5 ° C.), the supernatant liquid was taken, trypsin was added, and
Stir at 8 ° C for 8 hours. Furthermore, this solution is acidic (pH 5.
0) and after centrifugation (8,000 rpm, 10 minutes,
(5 ° C.) neutralized (pH 7.0), and using a dialysis membrane to remove substances having a molecular weight of 10,000 or less, SOD activity 23,
A bovine liver extract having 000 units / ml was obtained.
【００２２】製造例 ５ トリ肝臓１ｋｇを冷生理食塩水で洗浄した後細切し、精
製水２．２ｋｇおよびエタール０．８ｋｇを加え、４０
℃で３時間攪拌しながら抽出する。次に、これを遠心分
離（８，０００ｒｐｍ、２０分間、５℃）後上清液を取
り、アクチナーゼＥを加え、３０℃で５時間攪拌する。
さらに、この溶液を酸性（ｐＨ４．５）にし、遠心分離
（８，０００ｒｐｍ、１０分間、５℃）後中性（ｐＨ
７．０）にし、透析膜で分子量１０，０００以下の物質
を取り除き、ＳＯＤ活性１７，０００ｕｎｉｔ／ｍｌを
有するトリ肝臓抽出液を得た。Production Example 5 1 kg of avian liver was washed with cold physiological saline and then finely chopped, and 2.2 kg of purified water and 0.8 kg of etal were added to 40
Extract at 3 ° C with stirring for 3 hours. Next, this is centrifuged (8,000 rpm, 20 minutes, 5 ° C.), the supernatant is taken, actinase E is added, and the mixture is stirred at 30 ° C. for 5 hours.
Furthermore, this solution was made acidic (pH 4.5), and after centrifugation (8,000 rpm, 10 minutes, 5 ° C.), it was neutralized (pH
7.0), and substances having a molecular weight of 10,000 or less were removed by a dialysis membrane to obtain an avian liver extract having an SOD activity of 17,000 units / ml.
【００２３】次に、本願発明の酵素分解液ならびにこれ
を配合した製剤の試験結果（効果データ）を示す。Next, the test results (effect data) of the enzyme-decomposed solution of the present invention and a formulation containing the same are shown.
【００２４】試験例 （１）胎盤または肝臓抽出液のＳＯＤ活性 以下の実験の結果、本発明の各臓器抽出液のＳＯＤ活性
は非常に安定であることがわかった。Test Example (1) SOD activity of placenta or liver extract As a result of the following experiment, the SOD activity of each organ extract of the present invention was found to be very stable.
【００２５】ａ）臓器エキスの抽出法 臓器（胎盤または肝臓）１ｋｇをミンチにし、精製水２
ｋｇを加え、４０℃で約３時間攪拌抽出する。この抽出
液を遠心分離（８，０００ｒｐｍ、２０分間、５℃）
し、上清液を１０％水酸化ナトリウム水溶液でｐＨを弱
塩基性（７．５）に調整し、アクチナーゼＥを添加し、
３０℃で５時間攪拌しながら、酵素分解する。これを弱
酸性（約ｐＨ５．０）にし、一夜放置後、遠心分離
（８，０００ｒｐｍ、１０分間、５℃）して上清液をと
る。さらに、この液のｐＨを中性（７．０）にして分子
量１０，０００以下の物質を取り除き、試験液とする。A) Extraction method of organ extract 1 kg of organ (placenta or liver) is minced and purified water 2
kg is added, and the mixture is extracted with stirring at 40 ° C. for about 3 hours. Centrifuge this extract (8,000 rpm, 20 minutes, 5 ° C)
Then, the pH of the supernatant was adjusted to be weakly basic (7.5) with a 10% aqueous sodium hydroxide solution, and actinase E was added,
Enzymatic decomposition is performed while stirring at 30 ° C. for 5 hours. It is made weakly acidic (about pH 5.0), left overnight, and then centrifuged (8,000 rpm, 10 minutes, 5 ° C.) to obtain a supernatant. Further, the pH of this solution is made neutral (7.0), and substances having a molecular weight of 10,000 or less are removed to obtain a test solution.
【００２６】ｂ）ＳＯＤ活性測定法 ０．０５Ｍ炭酸ナトリウム緩衝液（ｐＨ１０．２）の
２．４ｍｌに、３ｍＭキサンチン、３ｍＭエデト酸二ナ
トリウム、０．１５％牛血清アルブミン、０．７５ｍＭ
ニトロブルーテトラゾリウムの各試液０．１ｍｌを加え
る。これに精製水で適当希釈の臓器抽出エキス試料０．
１ｍｌを加え、２５℃で１０分間放置後、キサンチンオ
キシダーゼ（約１ｕｎｉｔ／ｍｌ）０．１ｍｌを加え
て、２５℃でインキュベートする。B) Method for measuring SOD activity In 2.4 ml of 0.05 M sodium carbonate buffer (pH 10.2), 3 mM xanthine, 3 mM disodium edetate, 0.15% bovine serum albumin, 0.75 mM
Add 0.1 ml of each test solution of nitroblue tetrazolium. Organ extract extract sample appropriately diluted with purified water.
After adding 1 ml and leaving at 25 ° C. for 10 minutes, 0.1 ml of xanthine oxidase (about 1 unit / ml) is added and incubated at 25 ° C.
【００２７】２０分後、６ｍＭ塩化銅溶液０．１ｍｌを
加えて反応を停止させ、５６０ｎｍの吸光度を測定す
る。After 20 minutes, 0.1 ml of 6 mM copper chloride solution is added to stop the reaction, and the absorbance at 560 nm is measured.
【００２８】吸光度の５０％阻害する濃度を１単位とす
る。One unit is the concentration at which 50% of the absorbance is inhibited.
【００２９】ｃ）臓器抽出液のＳＯＤ活性の経時安定性 上記の試験液（本発明の抽出液）、比較液（上記試験例
において酵素分解および分子量分画をしないものを比較
例１とし、酵素分解はするが分子量分画をしないものを
比較例２とした）を５，２０，４５℃で１か月間保存
し、２，１０，１６，３０日目に外観の変化（沈澱、濁
り、異臭の有無）を観察するとともに、ＳＯＤ活性の変
化を測定した。C) Stability of SOD activity of organ extract over time The above test solution (extract of the present invention) and comparative solution (the one which is not subjected to enzymatic decomposition and molecular weight fractionation in the above test example is referred to as Comparative Example 1) A sample that decomposed but did not undergo molecular weight fractionation was designated as Comparative Example 2) was stored at 5,20,45 ° C for 1 month, and changes in appearance (precipitation, cloudiness, offensive odor) on 2, 10, 16, 30 days. The presence or absence of) was observed and the change in SOD activity was measured.
【００３０】結果を表１〜表４に示す。The results are shown in Tables 1 to 4.
【００３１】[0031]
【表１】 [Table 1]
【００３２】[0032]
【表２】 [Table 2]
【００３３】[0033]
【表３】 [Table 3]
【００３４】[0034]
【表４】 [Table 4]
【００３５】以上のように、本発明の各臓器抽出液は、
すべての温度条件においてＳＯＤ活性の低下は殆ど見ら
れず、安定であることが確認された。As described above, each organ extract of the present invention is
It was confirmed that SOD activity was hardly decreased under all temperature conditions, and that it was stable.
【００３６】また、外観の変化も認められなかった。No change in appearance was observed.
【００３７】次に外用剤組成物の具体的な処方例を示す
が、本発明はかかる実施例にのみに限定されるものでは
ない。Specific formulation examples of the external preparation composition are shown below, but the present invention is not limited to such examples.
【００３８】〔処方例〕 処方例１（クリーム） （重量％） ポリオキシエチレンオレイルエーテル（Ｐ．Ｏ．Ｅ．Ｏ） １．６０ モノステアリン酸グリセリン ３．００ サラシミツロウ ２．８０ セタノール ３．００ ステアリン酸 １．７５ 流動パラフィン ７．１０ パルソール１７８９ ０．５０ スクワラン ４．５０ グリセリン ２．５０ カーボポール９４０ ０．０８ クレワットＮ ０．０１ 製造例３で製造したブタ胎盤抽出液 ０．１０ 精製液 ７３．０６ この他に少量の香料および防腐剤を添加した。[Formulation Example] Formulation Example 1 (Cream) (% by weight) Polyoxyethylene oleyl ether (PEO) 1.60 Glycerin monostearate 3.00 Salix beeswax 2.80 Cetanol 3.00 Stearic acid 1.75 Liquid paraffin 7.10 Parsol 1789 0.50 Squalane 4.50 Glycerin 2.50 Carbopol 940 0.08 Clewat N 0.01 Porcine placenta extract prepared in Production Example 3 0.10 Purified solution 73 0.06 In addition to this, a small amount of perfume and preservative was added.
【００３９】 処方例２（乳液） （重量％） スクワラン ５．００ ワセリン ２．００ ミツロウ ０．５０ ソルビタンセスキオレイン酸エステル １．２０ プロピレングリコール ５．００ エタノール ５．００ カルボキシビニルポリマー（１％水溶液） ２０．００ 水酸化カリウム ０．１０ 製造例１で製造したウシ胎盤抽出液 １０．００ 精製液 ５１．６０ この他に少量の香料、防腐剤および酸化防止剤を添加し
た。Formulation Example 2 (Emulsion) (wt%) Squalane 5.00 Vaseline 2.00 Beeswax 0.50 Sorbitan sesquioleate ester 1.20 Propylene glycol 5.00 Ethanol 5.00 Carboxyvinyl polymer (1% aqueous solution) 20.00 Potassium hydroxide 0.10 Bovine placenta extract produced in Production Example 1 10.00 Purified solution 51.60 In addition to this, a small amount of perfume, preservative and antioxidant was added.
【００４０】処方例３（乳液） 処方例２において、「製造例１で製造したウシ胎盤抽出
液」の代わりに、「製造例２で製造したウマ肝臓抽出
液」を用いた処方を処方例３とした。Formulation Example 3 (Emulsion) In Formulation Example 2, a formulation using "horse equine liver extract produced in Production Example 2" in place of "Bovine placenta extract produced in Production Example 1" is used. And
【００４１】処方例４（乳液） 処方例２において、「製造例１で製造したウシ胎盤抽出
液」の代わりに、「製造例５で製造したトリ肝臓抽出
液」を用いた処方を処方例４とした。Prescription Example 4 (Emulsion) In Prescription Example 2, a prescription using "Avian liver extract produced in Production Example 5" in place of "Bovine placenta extract produced in Production Example 1" is used. And
【００４２】 処方例５（化粧水） （重量％） クエン酸 ０．４０ 炭酸カルシウム ０．２０ エタノール ５．００ プロピレングリコール ９．００ 製造例４で製造したウシ肝臓抽出液 ３０．００ 精製液 ５５．４０ この他に少量の香料および防腐剤を添加した。Formulation example 5 (lotion) (% by weight) Citric acid 0.40 Calcium carbonate 0.20 Ethanol 5.00 Propylene glycol 9.00 Produced liquid of bovine liver 30.00 Purified liquid produced in Production example 4 55. 40 In addition to this, a small amount of perfume and preservative was added.
【００４３】 処方例６（パック） （重量％） ビーガム ５．００ スクワラン ２．００ プロピレングリコール ５．００ 酸化亜鉛 １０．００ エタノール ５．００ 製造例２で製造したウマ肝臓抽出液 ２．００ 精製水 ６１．００ この他に少量の香料および防腐剤を添加した。Formulation Example 6 (pack) (% by weight) Veegum 5.00 Squalane 2.00 Propylene glycol 5.00 Zinc oxide 10.00 Ethanol 5.00 The horse liver extract prepared in Production Example 2 2.00 Purified water 61.00 In addition to this, a small amount of perfume and preservative was added.
【００４４】 処方例７（エッセンス） （重量％） カルボキシビニルポリマー（１％水溶液） １０．００ グリセリン ２０．００ エタノール １．００ ヒアルロン酸ナトリウム（１％水溶液） １０．００ 製造例２で製造したウマ肝臓抽出液 １０．００ 精製水 ４９．００ この他に少量の香料および防腐剤を添加した。Formulation Example 7 (Essence) (wt%) Carboxyvinyl polymer (1% aqueous solution) 10.00 Glycerin 20.00 Ethanol 1.00 Sodium hyaluronate (1% aqueous solution) 10.00 Horses produced in Production Example 2 Liver extract 10.00 Purified water 49.00 In addition to this, a small amount of perfume and preservative was added.
【００４５】 処方例８（ヘアトニック） （重量％） エタノール（９５％） ７５．００ グリセリン ５．００ 製造例４で製造したウシ肝臓抽出液 ５．００ 精製水 １５．００ この他に少量の香料および防腐剤を添加した。Formulation Example 8 (Hair Tonic) (wt%) Ethanol (95%) 75.00 Glycerin 5.00 Bovine liver extract produced in Production Example 4 5.00 Purified water 15.00 In addition to this, a small amount of fragrance And preservatives were added.
【００４６】[0046]
【発明の効果】本発明によれば、安定なＳＯＤ活性を有
する種々の胎盤または肝臓抽出液を得ることができ、こ
れを自明の外用剤基剤に配合することにより、ＳＯＤ本
来の作用がいかんなく発揮される、安全で、商品価値の
損なわれない外用剤組成物が提供される。INDUSTRIAL APPLICABILITY According to the present invention, various placenta or liver extracts having stable SOD activity can be obtained, and by incorporating this into an obvious external preparation base, the original action of SOD can be obtained. Provided is a safe external composition for external use that does not impair the commercial value.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ｃ１２Ｎ 9/50 7823−4Ｂ 9/76 7823−4Ｂ Ｃ１２Ｐ 21/06 8214−4Ｂ ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location C12N 9/50 7823-4B 9/76 7823-4B C12P 21/06 8214-4B
Claims (2)
酵素分解し、分子量１０，０００以下の物質を除去して
得られる安定なＳＯＤ活性を有する抽出液。1. An extract having a stable SOD activity, which is obtained by enzymatically decomposing a placenta or liver extract with a protease to remove substances having a molecular weight of 10,000 or less.
酵素分解し、分子量１０，０００以下の物質を除去して
得られる安定なＳＯＤ活性を有する抽出液を含有するこ
とを特徴とする外用剤組成物。2. An external preparation composition containing an extract having a stable SOD activity obtained by enzymatically decomposing a placenta or liver extract with a protease to remove substances having a molecular weight of 10,000 or less. ..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09772091A JP3272743B2 (en) | 1991-04-26 | 1991-04-26 | Placenta or liver extract having stable SOD activity and external preparation composition containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09772091A JP3272743B2 (en) | 1991-04-26 | 1991-04-26 | Placenta or liver extract having stable SOD activity and external preparation composition containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0578252A true JPH0578252A (en) | 1993-03-30 |
| JP3272743B2 JP3272743B2 (en) | 2002-04-08 |
Family
ID=14199731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09772091A Expired - Fee Related JP3272743B2 (en) | 1991-04-26 | 1991-04-26 | Placenta or liver extract having stable SOD activity and external preparation composition containing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3272743B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
| CN105456291A (en) * | 2015-12-31 | 2016-04-06 | 甘肃普尔康药业有限公司 | Large-scale production technology of liver extract |
| WO2018155525A1 (en) * | 2017-02-23 | 2018-08-30 | ゼリア新薬工業株式会社 | Anti-inflammatory agent |
| JP2019206495A (en) * | 2018-05-30 | 2019-12-05 | 株式会社粧薬研究所 | Agent containing horse placenta extract as active ingredient |
| KR102503124B1 (en) * | 2022-08-18 | 2023-02-23 | 주식회사 에이바이오머티리얼즈 | Method for preparing sheep placenta extract containing high content of amino acid and cosmetic composition comprising the extract |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108179141A (en) * | 2018-03-28 | 2018-06-19 | 西安瑞仁生物技术有限公司 | A kind of plant rennet extracting method and plant rennet obtained |
-
1991
- 1991-04-26 JP JP09772091A patent/JP3272743B2/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
| CN105456291A (en) * | 2015-12-31 | 2016-04-06 | 甘肃普尔康药业有限公司 | Large-scale production technology of liver extract |
| WO2018155525A1 (en) * | 2017-02-23 | 2018-08-30 | ゼリア新薬工業株式会社 | Anti-inflammatory agent |
| KR20190119039A (en) * | 2017-02-23 | 2019-10-21 | 제리아 신야쿠 고교 가부시키 가이샤 | Anti-inflammatory |
| JP2019206495A (en) * | 2018-05-30 | 2019-12-05 | 株式会社粧薬研究所 | Agent containing horse placenta extract as active ingredient |
| KR102503124B1 (en) * | 2022-08-18 | 2023-02-23 | 주식회사 에이바이오머티리얼즈 | Method for preparing sheep placenta extract containing high content of amino acid and cosmetic composition comprising the extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3272743B2 (en) | 2002-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3532244B2 (en) | Mucopolysaccharide fragmentation inhibitor, active oxygen scavenger and cosmetic | |
| JP2597084B2 (en) | Cosmetic composition | |
| JPH0925225A (en) | Skin external agent and production of active component for the agent | |
| JPH05230100A (en) | Protein fraction, its isolation, effective substance concentrate containing said fraction and preparation for skin care and/or medical treatment of inflammatory skin | |
| JPH09143063A (en) | Composition suitable for external use | |
| EP1908455A1 (en) | Hair care preparation | |
| CN103547254B (en) | Containing the wrinkle improvement compositions from the composition of Placenta Hominis | |
| JP2001122757A (en) | Active oxygen scavenger, antioxidant and cosmetic | |
| JP5983952B2 (en) | Method for producing cosmetic composition | |
| JP3272743B2 (en) | Placenta or liver extract having stable SOD activity and external preparation composition containing the same | |
| JP3263409B2 (en) | External preparation for skin | |
| JP2009084212A (en) | Involucrin production promoter | |
| JP5101769B2 (en) | Antibiotic antioxidant or preventive agent | |
| EP0207499A2 (en) | Use of Kojic acid or its beta-cyclodextrin inclusion complex for the prevention of elastosis | |
| JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
| JP2002284632A (en) | Extinction substance for superoxide anion extracted from sake lees as effective component | |
| EP0909557A1 (en) | Use of honey as an agent for decreasing micro-organisms adhesion | |
| CN115350109A (en) | Cosmetic composition for skin whitening or skin wrinkle improvement and method for producing the same | |
| JPH07309739A (en) | Suppressant for fragmentation of mucopolysaccharides and cosmetic | |
| JP3413220B2 (en) | Skin roughness improver | |
| JPS61205204A (en) | External preparation for skin | |
| US4908206A (en) | Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them | |
| JPH08198725A (en) | Skin cosmetic and hair cosmetic | |
| JP2000212058A (en) | Skin cosmetic, active oxygen eliminator, esterase inhibitor, and collagenase inhibitor | |
| JP3172599B2 (en) | Cell activator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20020115 |
|
| LAPS | Cancellation because of no payment of annual fees |